EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better

Omar Mhaimeed, Zain A Burney, Stacey L Schott, Payal Kohli, Francoise A Marvel, Seth S Martin

American Journal of Preventive Cardiology · 2024-06 · 18 · 100649

DOI: 10.1016/j.ajpc.2024.100649 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Preventive Cardiology, 2024-06. Verfasst von Omar Mhaimeed und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, United States. Die Arbeit wurde bisher 129-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cumulative exposure to low-density lipoprotein cholesterol (LDL-C) is a key driver of atherosclerotic cardiovascular disease (ASCVD) risk. An armamentarium of therapies to achieve robust and sustained reduction in LDL-C can reduce ASCVD risk. The gold standard for LDL-C assessment is ultracentrifugation but in routine clinical practice LDL-C is usually calculated and the most accurate calculation is the Martin/Hopkins equation. For primary prevention, consideration of estimated ASCVD risk frames decision making regarding use of statins and other therapies, and tools such as risk enhancing factors and coronary artery calcium enable tailoring of risk assessment and decision making. In patients with diabetes, lipid lowering therapy is recommended in most patients to reduce ASCVD risk with an opportunity to tailor therapy based on other risk factors. Patients with primary hypercholesterolemia and familial hypercholesterolemia (FH) with baseline LDL-C greater than or equal to 190 mg/dL are at elevated risk, and LDL-C lowering with high-intensity statin therapy is often combined with non-statin therapies to prevent ASCVD. Secondary prevention of ASCVD, including in patients with prior myocardial infarction or stroke, requires intensive lipid lowering therapy and lifestyle modification approaches. There is no established LDL-C level below which benefit ceases or safety concerns arise. When further LDL-C lowering is required beyond lifestyle modifications and statin therapy, additional medications include oral ezetimibe and bempedoic acid, or injectables such as PCSK9 monoclonal antibodies or siRNA therapy. A novel agent that acts independently of hepatic LDL receptors is evinacumab, which is approved for patients with homozygous FH. Other emerging agents are targeted at Lp(a) and CETP. In light of the expanding lipid treatment landscape, this manuscript reviews the importance of early, intensive, and sustained LDL-C-lowering for primary and secondary prevention of ASCVD.

Schlagwörter

Stichwörter der Autor:innen

Atherosclerotic cardiovascular diseaseLDL cholesterolLipid loweringNon-statinPrimary preventionSecondary preventionStatins

Autor:innen und Institutionen

  • Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, United States.
  • Department of Medicine, Cleveland Clinic, Cleveland, OH, United States.
  • Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
  • Department of Cardiology, University of Colorado Anschutz, Aurora, CO, United States.
  • Department of Cardiology, Veterans Affairs Hospital, Aurora, CO, United States.
  • Cherry Creek Heart, Aurora, CO, United States.

Zitieren

APA

Mhaimeed, O., Burney, Z. A., Schott, S. L., Kohli, P., Marvel, F. A., & Martin, S. S. (2024). The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better. American Journal of Preventive Cardiology, 18, 100649. https://doi.org/10.1016/j.ajpc.2024.100649

Vancouver

Mhaimeed O, Burney ZA, Schott SL, Kohli P, Marvel FA, Martin SS. The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better. American Journal of Preventive Cardiology. 2024;18:100649. doi:10.1016/j.ajpc.2024.100649

BibTeX
@article{Mhaimeed2024,
  author = {Mhaimeed, Omar and Burney, Zain A and Schott, Stacey L and Kohli, Payal and Marvel, Francoise A and Martin, Seth S},
  title = {The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better},
  journal = {American Journal of Preventive Cardiology},
  year = {2024},
  volume = {18},
  pages = {100649},
  doi = {10.1016/j.ajpc.2024.100649}
}
Kostenlos starten →